What happens when you stop taking a GLP-1 (Ozempic, Wegovy, Mounjaro)?

The short answer

GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) manage obesity rather than cure it, so stopping reliably brings back appetite and, for most people, a meaningful share of the lost weight — in trials, roughly two-thirds of the weight came back within a year of stopping semaglutide, and tirzepatide withdrawal regained at least 25% of lost weight in most participants, with blood-pressure and metabolic gains reversing too. The "I feel worse off than on" experience is real, but it's the underlying condition returning, not a drug-withdrawal syndrome.

Evidence tier: Tier 1 for the weight-regain trial data; Tier 2 for the "why you feel worse" mechanism. This is education, not medical advice — stopping or changing a GLP-1 is a clinician decision.

The key points:

• Appetite returns — "food noise" comes back, often within weeks
• Most weight comes back — ~two-thirds regain after semaglutide in trials
• Cardiometabolic gains reverse — blood pressure, blood sugar, lipids drift back
• It's not withdrawal — it's your underlying biology re-emerging, not dependence

This pairs with our guide on tapering off GLP-1s without rebound.

Why do you regain weight after stopping?

Evidence tier: 1 — large randomized withdrawal trials.

The regain is well-documented and largely expected, because GLP-1s treat obesity as the chronic condition it is — they manage it, they don't cure it. In the STEP-4 trial, people who lost weight on semaglutide and then switched to placebo regained about two-thirds of their lost weight over the following ~year, while those who continued lost a little more (Rubino 2021, STEP-4). Tirzepatide shows the same pattern: in SURMOUNT-4, stopping the drug led most participants to regain at least 25% of their lost weight — many regained far more — while continued treatment maintained the loss (SURMOUNT-4 analysis).

The mechanism isn't mysterious. These drugs work by suppressing appetite and slowing gastric emptying; remove the drug and that suppression ends, so hunger and food intake climb back toward baseline. On top of that, the body defends a higher "set point" after weight loss through hormonal and metabolic adaptation — appetite hormones shift to encourage eating, and resting energy expenditure can fall. This is true of essentially all weight loss, not just GLP-1s, but the contrast feels sharper because the appetite suppression switched off abruptly. The practical implication, which surprises many people, is that GLP-1s are best understood as long-term or maintenance therapy — like blood-pressure medication — rather than a short course you finish. For the full picture of how these drugs work, see the GLP-1 complete guide.

Why do some people feel worse off than on?

Evidence tier: 2 — consistent with the biology and reports.

This is one of the most common things people post about, and it's genuinely worth understanding. When you stop, several things rebound at once. Appetite and "food noise" — the constant background thoughts about food that GLP-1s famously quiet — come roaring back, and after months of relief that can feel distressing, even more intense than before by contrast. Cardiometabolic improvements reverse: in the SURMOUNT-4 data, blood pressure, blood sugar, and lipid gains drifted back toward baseline as weight returned, so people can feel the return of the very symptoms the drug had improved. And there's a real psychological dimension — watching hard-won progress reverse, with hunger you can't easily control, is demoralizing in a way that compounds the physical changes.

What this is not is a classic withdrawal syndrome. GLP-1s aren't addictive and don't cause physical dependence the way opioids or benzodiazepines do — there's no neuro-adaptive withdrawal state. What feels like "withdrawal" is the underlying condition re-emerging once the treatment stops: the appetite, the metabolic tendencies, and sometimes the reflux or joint symptoms that the weight loss had eased. Naming it accurately matters, because the solution isn't to "detox" or push through — it's to recognize that the biology was being managed, and to plan accordingly with a clinician. (Distinct from this are the GI side effects covered in managing GLP-1 side effects, which generally fade after stopping, not worsen.)

Is there a true GLP-1 withdrawal or rebound syndrome?

Evidence tier: 2 — emerging clinical understanding.

Short answer: there's rebound, but not addiction-style withdrawal. The "rebound" is real and has two components. The first is rebound appetite — because the drug was actively suppressing hunger, stopping can leave appetite feeling temporarily higher than your true baseline as the system re-equilibrates, which is why some people overeat in the first weeks off. The second is rebound of the underlying disease — weight, blood sugar, and blood pressure returning. Both are predictable; neither reflects the drug having "broken" your metabolism permanently.

Some clinicians and researchers are exploring whether tapering (rather than abruptly stopping) softens the rebound, and whether a lower maintenance dose can hold most of the benefit at lower cost and side-effect burden. The evidence base for tapering specifically is still thin, but the logic is sound and it's an active area — we cover the practical approaches in tapering off GLP-1s without rebound. The honest framing for anyone deciding to stop: expect appetite to return, expect some regain, and treat it as a managed transition with a plan, not a clean exit.

How do you stop a GLP-1 without major rebound?

Evidence tier: 2–3 — reasonable strategies, limited controlled data.

If stopping is the goal — cost, side effects, pregnancy planning, or simply wanting off — a few things stack the odds in your favor, and all of them belong in a conversation with your prescriber rather than a solo decision. Taper rather than quit cold, where feasible, to ease the appetite rebound. Consider a maintenance dose instead of full discontinuation: many people hold most of their results on a lower dose with fewer side effects, which is increasingly how these drugs are used long-term. Build the lifestyle scaffolding before you stop, not after — a protein-forward diet (protect muscle, since rapid loss and regain churns lean mass; see peptides and fasting for the muscle-preservation logic), consistent resistance training, and sleep all blunt regain. And set expectations: some regain is normal and not a personal failure; the goal is a soft landing, not zero change.

For people stopping due to pregnancy or another medical reason, the timeline and approach differ and are genuinely clinician territory. And if the reason for stopping is side effects or cost, it's worth asking whether a dose adjustment or a switch to a different GLP-1 solves the problem without giving up the benefit entirely. The decision to stop is legitimate and personal — the point is to do it deliberately.

It also helps to reframe what "success" looks like after stopping. Holding onto even half of your loss is a meaningful health win, and a partial regain that leaves you lighter, fitter, and with better habits than before is a genuinely good outcome — not the failure that the all-or-nothing framing online suggests. Many people cycle: a period on the drug, a period off with lifestyle holding the line, then back on if needed. That intermittent pattern is increasingly normal and nothing to be ashamed of. The unhelpful story is the one where any regain means the whole effort was pointless; the accurate story is that obesity is chronic, treatment is a tool you can pick up and put down with a plan, and the long game is what matters.

Limitations

This is educational content, not medical advice.

• Most people regain a substantial share of lost weight after stopping — this is expected, not failure.
• Cardiometabolic benefits reverse as weight returns (blood pressure, glucose, lipids).
• GLP-1s are not addictive — "withdrawal" feelings are the underlying condition returning.
• Don't stop or change dose on your own — especially if you take insulin, a sulfonylurea, or other medications.
• Tapering evidence is still limited — the logic is sound but controlled data is thin.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Stopping a GLP-1 predictably brings back appetite and most of the lost weight — about two-thirds regain after semaglutide in STEP-4, and at least 25% regain for most people after tirzepatide in SURMOUNT-4, with cardiometabolic gains reversing alongside. The "worse off than on" feeling is real but it's the underlying condition and appetite re-emerging, not an addiction-style withdrawal: these drugs manage obesity rather than cure it, so they work best as long-term or maintenance therapy. If you do stop, taper where you can, consider a maintenance dose, build the diet-and-training scaffolding first, and do it with a clinician — a planned soft landing beats an abrupt exit.

Related on this site

• Tapering off GLP-1s without rebound: maintenance protocols
• Switching between GLP-1s
• Managing GLP-1 side effects
• GLP-1 complete guide
• Peptides and fasting: protecting muscle
• Our evidence-tier framework

References

• Rubino D, Abrahamsson N, Davies M, et al. 2021. Effect of continued weekly subcutaneous semaglutide vs placebo on weight-loss maintenance (STEP-4). JAMA. PMID 33755728 — ~two-thirds regain after stopping semaglutide.
• Aronne LJ, et al. 2024–2025. Continued vs withdrawn tirzepatide for weight maintenance (SURMOUNT-4) and cardiometabolic reversal post hoc analysis. JAMA / JAMA Intern Med. SURMOUNT-4 analysis — regain and cardiometabolic reversal on withdrawal.
• Wilding JPH, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. PMID 33567185 — baseline efficacy context.
• GLP-1 discontinuation and weight regain (literature). PubMed — body of withdrawal evidence.